Carrum Health

Belkins
Healthcare is unreasonably complex and costly. At Carrum Health, we’re applying a common sense approach to simplify the payment model and produce greater value for employers and their employees. We do so by directly connecting progressive self-insured employers to top-quality regional healthcare providers through the industry’s first comprehensive bundled payment solution. Our innovative platform reimagines how care is paid for and delivered, improving the value of health benefits for employers and their members.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SOLIGENIX ANNOUNCED PUBLICATION OF PRE-CLINICAL IMMUNOGENICITY STUDIES FOR A NOVEL COVID-19 VACCINE

PR Newswire | July 29, 2020

news image

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant.&nbs...

Read More

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

news image

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

news image

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More

CELL AND GENE THERAPY

GRITSTONE BIO AND CEPI EXPAND VACCINE AGREEMENT TO TACKLE OMICRON VARIANT

Gritstone bio | December 07, 2021

news image

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...

Read More
news image

SOLIGENIX ANNOUNCED PUBLICATION OF PRE-CLINICAL IMMUNOGENICITY STUDIES FOR A NOVEL COVID-19 VACCINE

PR Newswire | July 29, 2020

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant.&nbs...

Read More
news image

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More
news image

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More
news image

CELL AND GENE THERAPY

GRITSTONE BIO AND CEPI EXPAND VACCINE AGREEMENT TO TACKLE OMICRON VARIANT

Gritstone bio | December 07, 2021

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us